摘要
目的 探究抗体D5F3及Survivin在非小细胞肺癌患者中的临床应用价值。方法 选取2012年10月~2014年6月期间于建德市第一人民医院经RT-PCR检测的200例非小细胞肺癌患者的石蜡包埋标本（包括EML4-ALK突变型和野生型）,应用ALK新型抗体D5F3及Survivin（CST公司生产）检测该基因蛋白表达情况,分别从阴性、阳性（＋~3＋）进行对比其敏感性和特异性。结果检测结果显示,（＋）符合率为15.78%,（＋＋）符合率为27.27%,（＋＋＋）符合率为87.5%,差异有统计学意义（P〈0.05）,Survivin蛋白在NSCLC组织中的表达与临床病理特征的关系Survivin蛋白表达的阳性率与分化程度相关（P〈0.05）,而与其他临床病理特征无相关,随分化程度降低,Survivin蛋白表达的阳性率显著增加。结论 D5F3及Survivin抗体在NSCLC患者高度的敏感性及特异性,具有筛选价值,节约社会资源,为广大肺癌患者服务。
Objective To investigate the clinical value of antibody D5F3 and Survivin in patients with non small cell lung cancer. Methods 2 0 0 araffin embedded specimens of patients with non small cell lung cancer tested by RT-PCR（ including EML4-ALK mutant and wild type） from October 012 to June 2014 were selected. The gene protein expression were tested by ALK new antibody D5F3 and the sensitivity and specificity were compared y negative and positive （ ＋ ？3 ＋ ）. Results T e s t results show （＋） t h e coi n c i d e n c e rate is 15. 78 %,（ ＋ ＋ ） the c o i n c i d e n c e rate is 27. 27% a n d （＋ ＋ ＋ ） compliance rate was 87. 5% , the difference was statistically significant （P 〈0. 05）. The expression of Survivin protein in NSCLC tissues was orrelated with clinicopathological features. The positive rate of Survivin protein expression was correlated with the degree of differentiation （ P 〈 0. 05 ）, ut not with other clinical and pathological features, with the decrease of differentiation, the positive rate of Survivin protein expression was significantly ncreased. Conclusion D5F3 and Survivin antibodies are highly sensitive and specific in patients with NSCLC, with the screening value, save social esources, for the majority of patients with lung cancer services.
出处
《中国生化药物杂志》
CAS
2017年第4期422-425,共4页
Chinese Journal of Biochemical Pharmaceutics
